YZR Capital

YZR is growing, so we moved! 🚀 Last week we hosted our office opening reception in Maria-Theresia-Straße in Munich. In the last two years, not only our portfolio grew significantly, but also our team. Hence, it was time for a larger office. With more than 60 fellow investors, portfolio founders, and YZR friends we inaugurated our office - with a not so successful but very fun "Fassanstich", and private Rikscha rides. Thank you everyone for coming, it was a blast! 🙏 #healthtech #venturecapital

Welcome to our portfolio, Esper Bionics ! 🦾 Esper Bionics is a pioneering US-based engineering company that develops the first bionic ecosystem in the world. It’s flagship product, the Esper Hand, made it on the cover of TIME magazine as one of the Best Innovations of 2022. We’re excited to share that we led the $5m round, which was joined by EBRD and u.ventures. The Esper Hand is perfect for comfortable use as a lifestyle device, with uniquely designed muscle sensors, providing users with better control compared to other prosthetics. Unlike most robotic arms that rely on just two sensors for all hand functions, the Esper Hand uses ~ 20 sensors with a cloud-based software platform that is housing its AI control algorithms built around it. However, Esper is not a prosthetic limb company: their vision is to develop next-generation sensors for widespread use, which will be licensed to other wearable manufacturers. Dima Gazda, Co-Founder & CEO at Esper Bionics states: "Our users are our inspiration to innovate and excel. We have received exceptional feedback from them, and we are committed to making the Esper Hand even more dexterous, ensuring it reaches everyone in need. By enhancing manufacturing, developing new types of sensors, and helping more people, we are getting closer to pushing the boundaries of human potential."   Congrats Dima Gazda, Anna Believantseva, Ihor Ilchenko, Kyrylo Perevozchykov, and their team! We are very happy to be on board! 👏   Read more about Esper on Sifted, link in 1st comment.   #healthtech #bionics

Meet us in Paris! 👋 Our Founding Partner, Markus Feuerecker, will be at the Goldman Sachs French Disruptive Technology Symposium in Paris on the 26th of June. If you're in town and keen to discuss the health tech industry or learn about YZR Capital, please reach out! #healthtech #venturecapital

Meet us in London! 👋   Our Founding Partner, Markus Feuerecker, will be at the J.P. Morgan European Healthcare Symposium in London on the 20th of June. If you're in town and keen to discuss the health tech industry or learn about YZR Capital, please reach out!   #healthtech #venturecapital

Meet us at HLTH Europe conference! 👋 Reinhard Meier, MD MBA and Paul Epple will be at HLTH Europe 2024 in Amsterdam next week. Feel free to shoot us a message if you're around, or meet us at our panel! 💰 Sales: Reclaiming healthcare's dirtiest word 📅 18.06.24, 10:40 - 11:20 at the Startup Stage Looking forward to join you on the panel Tim Juergens | Marius Mainz | Jamie Lu | Maximilian Greschke #hlth #hltheurope #healthtech

health.tech conference - thank you for having us! Here are our key learnings from the YZR-curated panels: 🎙️ 𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐃𝐞𝐛𝐭 𝐏𝐚𝐧𝐞𝐥: What a lively and entertaining discussion with Chris Church (Blackrock), Daniel Mallon (Claret Capital), Christian Köhler (Filu), George van Dorp (Fundflow), and Humphrey Nokes (Bootstrap Europe), moderated by Reinhard. The panel explored the strategic integration of venture debt financing in healthcare startups, offering key insights: • 𝗔𝘀𝘀𝗲𝘁-𝗕𝗮𝘀𝗲𝗱 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗻𝗴 Revenue isn't essential; asset value is crucial. • 𝗜𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗔𝘀𝘆𝗺𝗺𝗲𝘁𝗿𝘆: VD providers hold the least information, after founders and VCs, requiring the most rights. • 𝗧𝗲𝗿𝗺𝘀: Expect low double-digit interest rates and warrants, typically 1/10th of equity raise. • 𝗖𝗿𝗲𝗮𝘁𝗲 𝗙𝗢𝗠𝗢: Founders should aim for at least three bids! • 𝗛𝗼𝘄 𝘁𝗼 𝗚𝗲𝘁 𝗩𝗗: Use platforms, leverage your VCs, or reach out directly. 🧬 𝐓𝐞𝐜𝐡𝐁𝐢𝐨 𝐏𝐚𝐧𝐞𝐥: With Viktor Matyas (Aignostics), Jonathan Baptista (Deeplife), Nicolas Wolikow (Cure51), and Michiel Scheffer (EIC), and Reinhard, this panel delved into the intersection of technology and biotech: • 𝗔𝗜 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗶𝗼𝗻: AI has accelerated the drug discovery and development process from years to days. • 𝗔𝗜 𝗶𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲: Identifying correlations is insufficient; understanding causal relations is essential. • 𝗗𝗮𝘁𝗮 𝗶𝘀 𝗸𝗲𝘆, interdisciplinary collaboration is essential. • 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 when integrating AI into traditional pharmaceutical workflows • 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗳𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸𝘀 may support or may hinder innovation in TechBio • 𝗙𝘂𝗻𝗱𝗶𝗻𝗴 𝗯𝘆 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗖𝗼𝘂𝗻𝗰𝗶𝗹 allows for scaling to European champions. Both panels showcased the transformative potential of innovation in healthcare, emphasizing the importance of strategic financing and responsible tech integration. Thank you to all participants for their valuable insights! #VentureDebt #TechBio #HealthTech

🌟 Deemea raised a €4m seed round to deploy its AI platform for clinical research! We are thrilled to partner with DEEMEA, a pioneering digital health startup revolutionizing biomedical research with its unique AI-guided software platform, the "DEEMEA Research Platform".   ✅ DEEMEA's platform excels in medical imaging, covering the entire clinical research process from data collection to statistical analysis. With advanced data management, automatic image annotation, and expert validation, it's a game-changer in clinical research.   🏥Trusted by numerous clinical sites and industry leaders across Europe, DEEMEA accelerates real-world studies and clinical trials, ensuring data traceability and reducing decision-making times and costs.   "This fundraising with Franco-German partners marks the acceleration of our development on a European scale to provide the research world with a comprehensive, collaborative, multi-site platform, cooperative between sponsors and investigators, thus strengthening the trust and commitment of the biomedical research ecosystem". Charlotte Pouchy, CEO of Deemea   💼 Together with our friends at Karista, we joined Deemea’s vision to transform clinical research with AI!   #HealthTech #BiomedicalResearch #AI #VentureCapital

Meet us at health.tech conference! 👋 Reinhard Meier, MD MBA, Paul Epple, and Christina Schmidt will be at health.tech in Munich this week. Feel free to shoot us a message if you're around, or meet us at one of our panels! Christian Köhler | Chris Church | Daniel Mallon | George van Dorp | Dima Gazda | Olena Skyrta | Jonathan Baptista | Simon Istolainen | Viktor Matyas #healthtech2024 #startups

🚀 Exciting news! Our portfolio company apoQlar, the creator of Holomedicine®, has closed a €10 million Series A funding round!   apoQlar's innovative CE marked and FDA approved VSI HoloMedicine® platform leverages AI and augmented reality to enhance surgical planning, medical education, and patient communication by providing 3D visualizations and real-time data integration, thus improving precision and understanding in medical procedures. apoQlar builds on cooperations with prestigious partners such as Mayo Clinic to advance patient care. The company is active with 6 offices across 3 continents, distributing their service globally.   Having been the first institutional investor leading apoQlar’s seed round, we are honored to be part of the group of investors including IFB Innovationsstarter GmbH enabling the expansion of apoQlar’s global footprint.   Congrats to Sirko Pelzl, Marc-Angelo Bisotti and the apoQlar team!   #Holomedicine #HealthTech #YZRCapital

Expertise, Expertise, Expertise! These three words summed up the essence of our UBS & YZR Capital #HealthTech VC dinner in Frankfurt's iconic OperaTower. Short summary: 💡 Maximilian Kunkel, CIO of UBS Germany, shared his deep expertise in global financial markets, in short: exciting times ahead. 🚀 Four of our fourteen portfolio companies presented their technology solutions and business strategies - thank you to Manuel Opitz, Charlotte Pouchy, Marc-Angelo Bisotti, Max Renneberg, for your inspiring talks! 💬 Best of all: networking with the attending industry leaders was a great way to stay ahead of the curve, e.g. we could match our entrepreneurs with potential partners and investors, fostering innovation and collaboration in the health tech space. A huge thank you to UBS hosting us Sükriya Aclan, CFEP Samuel Menghistu, Jonas Brachtel and to everyone who joined! Yannick Sebastian Müller, Tom Solo Dr. Matthias Koch Dr. Ole Dammann, Reinhard Meier, MD MBA Markus Feuerecker, Ándy Reschke, Christof Hettich, Christopher Lisfeld. #healthtech #venturecapital #privatebanking #expertise #community